Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

Published on January 21, 2022

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

Continue reading on website
Other news

European spend management platform Moss raises $86 million

January 21, 2022
Berlin-based startup Moss announced earlier this week that it has closed a new $86 million Series B funding round (€75 million). The company offers corporate credit cards for small and medium companies so that they can more easily spend and track their spending.Following today’s funding round, Moss has reached a valuation of $573 million (€500 million). Tiger Global Management is leading the Serie

Elizabeth Warren Says Elon Musk Launches Personal Attacks On Her, Rather Than Actually Discussing the Tax System

January 21, 2022
Musk called Warren "Senator Karen" in December after she said he pays too little tax.